While there isn’t a lot of hard science out yet, there have been benefits seen for both patients and practices when integrated cancer care teams are used, Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.
While there isn’t a lot of hard science out yet, there have been benefits seen for both patients and practices when integrated cancer care teams are used, Thomas Asfeldt, MBA, RN, director of Outpatient Cancer Services at Sanford Cancer Center.
Transcript
When integrated cancer care teams are done right, what are the benefits to both the patient and the practice or hospital?
There’s not a lot of hard science, yet, to say, “Here, definitely, are the benefits,” but there are certainly some science coming out saying, “Here’s the data, here’s what it shows.” There’s certainly some things that both providers and patients can expect.
For patients, we’ve certainly seen data that shows patients can expect to go from diagnosis to treatment in a much shorter period of time in the integrated cancer care setting. That’s, I think very clear—I’ve seen that in multiple studies and in my own institution and papers that I’ve reviewed that have been published. Patients can also expect that their providers have communicated better, so when they meet with one group—whether that’s a physician or a nonphysician provider or another part of their care team—that they’re getting the same message and that everyone on the care team knows what the plan of care is for the patient. That’s hugely beneficial for the patient. The patient can expect that, ultimately, they’re going to have higher satisfaction with their care because all those pieces are going together.
For the practice, there is benefits, as well. I think the first piece that I’ve seen in our setting is that the providers, I think, have higher practice satisfaction, because they’re in a tight collaboration with all of the other providers. And, so, the professional practice satisfaction goes up, because they’re no longer just working in their tunnel vision, so to speak, or trying to get patients through on a daily basis. But they’re in that regularly collaborative environment with their other colleagues, which is very important.
The second thing that they’ll see, providers, is that there’s going to be less re-work. So, they’re not doing an exam or a test on a patient and then finding out 2 days later that, “Oh, this was done already. Why am I doing this over again when this was already done?” Just simply because they didn’t have the information, or they didn’t know about. So, there’s less work, and that creates more efficiencies. Ultimately, if the practice wants to, when you’re more efficient, they can see more patients in the same amount of time. So, I think that’s also greatly beneficial for the practice.
So, it’s definitely good for patients, and it’s good for the practice. It’s a very collegial environment for the practice, so it’s definitely a positive thing for patients and the environment that we all work in.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More